Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

CELGENE CORPORATION

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer

Phase 1

Completed

Conditions: Hematologic Malignancy
Malignant Lymphoma

Interventions: Drug: Romidepsin
Drug: Rifampin

First Posted Date: 2011-03-29

Last Posted Date: 2019-11-25

Lead Sponsor: Celgene

Target Recruit Count: 14

Registration Number: NCT01324323

Locations: 🇬🇧
Sarah Cannon Research UK, London, United Kingdom
🇺🇸
Sarah Canon Research Institute, Nashville, Tennessee, United States
🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States

Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Drug: pomalidomide

First Posted Date: 2011-03-29

Last Posted Date: 2019-11-19

Lead Sponsor: Celgene

Target Recruit Count: 74

Registration Number: NCT01324947

Locations: 🇪🇸
Hospital de Donostia - Hematology, Guipúzcoa, Spain
🇨🇦
Royal Victoria Hospital, Montreal, Quebec, Canada
🇦🇺
Border Medical Oncology, Wodonga, Australia

and more 88 locations

Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer

Phase 1

Completed

Conditions: Hematologic Malignancy
Malignant Lymphoma

Interventions: Drug: Romidepsin
Drug: Ketoconazole

First Posted Date: 2011-03-29

Last Posted Date: 2019-11-25

Lead Sponsor: Celgene

Target Recruit Count: 15

Registration Number: NCT01324310

Locations: 🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇬🇧
Sarah Cannon Research UK, London, United Kingdom

Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: ACY-1215

First Posted Date: 2011-03-28

Last Posted Date: 2017-04-06

Lead Sponsor: Celgene

Target Recruit Count: 120

Registration Number: NCT01323751

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

and more 3 locations

A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Dexamethasone
Drug: pomalidomide

First Posted Date: 2011-03-09

Last Posted Date: 2018-10-24

Lead Sponsor: Celgene

Target Recruit Count: 455

Registration Number: NCT01311687

Locations: 🇧🇪
CHU UCL Mont-Godinne-Dinant asbl, Yvoir, Belgium
🇷🇺
St. Petersburg Research Institute of Hematology and Blood Transfusion, St. Petersburg, Russian Federation
🇷🇺
State Institution Moscow Regional Research Clinical Institute, Moscow, Russian Federation

and more 91 locations

VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas

Phase 1

Terminated

Conditions: Low Grade B Cell Lymphoma

Interventions: Drug: VTX-2337 plus radiotherapy

First Posted Date: 2011-02-03

Last Posted Date: 2019-09-25

Lead Sponsor: Celgene

Target Recruit Count: 2

Registration Number: NCT01289210

Locations: 🇺🇸
Stanford Cancer Center, Stanford, California, United States

A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)

Phase 2

Terminated

Conditions: Fibrosis
Interstitial Lung Disease
Idiopathic Pulmonary Fibrosis
Pulmonary Fibrosis
Lung Diseases, Interstitial

Interventions: Drug: CC-930
Other: Placebo

First Posted Date: 2010-09-17

Last Posted Date: 2019-11-19

Lead Sponsor: Celgene

Target Recruit Count: 28

Registration Number: NCT01203943

Locations: 🇨🇦
Vancouver General Hospital/University of British Columbia, Vancouver, British Columbia, Canada
🇺🇸
University of Louisville, Louisville, Kentucky, United States
🇺🇸
Baylor College of Medicine, Houston, Texas, United States

and more 19 locations

Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS)

Phase 4

Completed

Conditions: Myelodysplastic Syndromes

Interventions: Drug: Azacitidine

First Posted Date: 2010-09-15

Last Posted Date: 2019-12-05

Lead Sponsor: Celgene

Target Recruit Count: 44

Registration Number: NCT01201811

Locations: 🇨🇳
Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City, Taiwan
🇨🇳
National Cheng Kung University Hospital, Tainan, Taiwan
🇨🇳
Changhua Christian Hospital, Changhua, Taiwan

and more 8 locations

Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 2

Completed

Conditions: Diffuse Large B-cell Lymphoma

Interventions: Drug: Gemcitabine
Drug: Lenalidomide
Drug: Oxaliplatin
Drug: Rituximab
Drug: Etoposide

First Posted Date: 2010-09-09

Last Posted Date: 2019-11-25

Lead Sponsor: Celgene

Target Recruit Count: 111

Registration Number: NCT01197560

Locations: 🇺🇸
Washington University Siteman Cancer Center, Saint Louis, Missouri, United States
🇦🇺
Royal Adelaide Hospital, Adelaide, Australia
🇦🇺
Princess Alexandra Hospital, Woolloongabba, Australia

and more 54 locations

An Extension to Study AZA PH GL 2003 CL 001 Allowing for Continuation of Azacitidine Treatment in Patients With Myelodysplastic Syndromes (MDS)

Phase 3

Completed

Conditions: Myelodysplastic Syndromes

Interventions: Drug: Azacitidine

First Posted Date: 2010-08-23

Last Posted Date: 2019-11-14

Lead Sponsor: Celgene

Target Recruit Count: 40

Registration Number: NCT01186939

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy